Localized $^{18}$F-fluorodeoxyglucose uptake at the pancreatic head during remission phase of autoimmune pancreatitis: A case report

YOSHIKUNI YONENAGA$^{1,2}$, FUMIKI KUSSIHATA$^1$, JOTA WATANABE$^3$, TAJI TOHYAMA$^1$, HITOSHI INOUE$^4$, ATSURO SUGITA$^5$ and YASUTSUIGU TAKADA$^4$

$^1$Department of Hepatobiliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295; $^2$Department of Surgery, Nagahama City Hospital, Nagahama, Shiga 526-8580; $^3$Pathology Division, Ehime University Hospital, Toon, Ehime 791-0295, Japan

Received February 4, 2015; Accepted March 15, 2016

DOI: 10.3892/ol.2016.4815

Abstract. Autoimmune pancreatitis (AIP) is a unique form of pancreatitis, histopathologically characterized by dense lymphoplasmacytic infiltration and fibrosis of the pancreas with obliterative phlebitis. AIP is associated with a good response to steroid therapy. Differentiation between AIP and pancreatic cancer to determine a preoperative diagnosis is often challenging, despite the use of various diagnostic modalities, including computed tomography (CT), magnetic resonance imaging and endoscopic retrograde cholangiopancreatography. It has been reported that $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG)-positron emission tomography (PET)/CT may be a useful tool for distinguishing between the two diseases. In the present case report, a 71-year-old male patient presented with a well-circumscribed, solitary, nodular and homogenous $^{18}$F-FDG uptake at the pancreatic head, while receiving maintenance steroid therapy in the remission phase of AIP; preoperatively, the patient had been strongly suspected of having pancreatic cancer. Pathological examination revealed post-treatment relapse of AIP. The present case highlights the diagnostic and management difficulties with AIP in the remission phase. In certain cases, it remains challenging to differentiate the two diseases, even using the latest modalities.

Introduction

Autoimmune pancreatitis (AIP) is a unique form of pancreatitis that is histopathologically characterized by dense lymphoplasmacytic infiltration and fibrosis of the pancreas with obliterative phlebitis (1). Pancreatic cancer is one of the leading causes of mortality in Japan and Western countries (2). This type of tumor is associated with poor prognosis, due to its aggressive biology and the difficulty in making an early diagnosis. Patients with AIP share numerous clinical features with pancreatic cancer patients, including advanced age, painless jaundice, weight loss, new-onset diabetes mellitus and elevated serum levels of carbohydrate antigen (CA) 19-9 (3). Such factors commonly render the differentiation between AIP and pancreatic cancer rather challenging; however, distinguishing between the two diseases is crucial, as their treatments and prognoses are vastly different (4). An accurate preoperative diagnosis of AIP is required in order to avoid unnecessary surgery and to achieve clinical remission with steroid therapy. $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography (PET)/computed tomography (CT) has been reported to assist with this differentiation (2,3,5). The current study reports the case of a patient who presented with a new localized $^{18}$F-FDG uptake at the pancreatic head and normal serum immunoglobulin G4 (IgG4) levels during the remission phase of AIP, and had been strongly suspected of having pancreatic cancer preoperatively. Written informed consent to publish was obtained from the patient.

Case report

A 71-year-old male patient was admitted to Shiritsu Oozu Hospital (Oozu, Japan) after presenting with worsening diabetes mellitus in April 2009. The patient had a history of two abdominal surgeries: A cholecystectomy and choledochojunostomy, due to choledocholithiasis 28 years prior to admission; and a right lateral hepatic sectoricotomy, due to intrahepatic stones 3 years prior to admission. AIP was suspected following a workup, which included examining the serum IgG4 levels and an $^{18}$F-FDG-PET/CT, and the patient was referred to the Ehime University Hospital (Toon, Japan). Abdominal ultrasonography and CT imaging (Brilliance 64; Philips, Tokyo, Japan) revealed enlargement of the pancreatic head and body (Fig. 1A and B). Endoscopic retrograde cholangiopancreatography (ERCP; JF-260V; Olympus Corporation, Tokyo, Japan) showed diffuse narrowing of the main pancreatic duct (MPD) in the pancreatic head and body (Fig. 1C). $^{18}$F-FDG-PET/CT (Discovery ST Elite; GE Healthcare Life Sciences, Hino, Japan), which had been performed during the previous hospital stay, revealed a strong and diffuse uptake of...
YONENAGA et al: LOCALIZED $^{18}$F-FDG UPTAKE AT THE PANCREATIC HEAD IN THE REMISSION PHASE OF AIP

The serum IgG4 level was markedly elevated (158 mg/dl; normal range, 4.8-105.0 mg/dl). A diagnosis of AIP was thereby established, and steroid therapy was initiated.

The initial oral prednisolone dose administered was 30 mg/day. Following the initiation of the steroid therapy, the enlargement of the pancreatic head and body markedly improved, the diffuse narrowing of the main pancreatic duct fully recovered (Fig. 2A-C), and the IgG4 level dropped to within normal limits. The oral steroid therapy regimen was as follows: The initial dose was administered daily for 2 weeks, followed by gradual tapering of the dose by 5 mg every 2 weeks, until a daily dose of 5 mg was reached. Subsequently, maintenance steroid therapy (5 mg/day) was administered, based on the Japanese consensus guidelines for the management of AIP (6).

At 10 months after the initiation of the steroid therapy, elevated serum levels of amylase (255 IU/l; normal range, 37-124 IU/l) and lipase (91 IU/l; normal range, 13-49 IU/l) were detected, and a CT scan revealed a 2-cm low-attenuation mass at the pancreatic head and dilation of the MPD (Fig. 3A and B). The patient was readmitted to the hospital due to a suspected relapse of AIP. Magnetic resonance imaging (MRI) revealed tumor-like enlargement at the pancreatic head, and obstruction of the MPD with dilatation of the upstream MPD. ERCP showed a ~2-cm long stricture of the MPD at the pancreatic head and a dilatation of the body and tail portion of MPD that measured 5 mm in diameter (Fig. 3C). Based on these radiographic findings, it was difficult to decide between recurrence of AIP and pancreatic cancer. The serum levels of CA19-9, duet pancreatic monoclonal antigen type 2, and Span-1 were normal. The serum level of carcinoembryonic antigen was slightly elevated (7.1 ng/ml; normal range, <5.0 ng/ml). The serum level of IgG4 was 106 mg/dl, which was below the cutoff value (≥135 mg/dl) of the Japanese clinical diagnostic criteria for AIP (1). $^{18}$F-FDG-PET/CT
Aquiduo PCA-7000B (Toshiba Medical Systems, Ootawara, Japan) showed a well-circumscribed, solitary, nodular and homogenous \(^{18}\)F-FDG uptake, with a maximum standardized uptake value of 7.82 at the location where the pancreatic head mass was identified by CT scan (Fig. 3D). No abnormal extra-pancreatic uptake of \(^{18}\)F-FDG was observed.

The patient was referred to the Department of Hepatobiliary-Pancreatic and Breast Surgery, Ehime University Hospital with a suspected diagnosis of concomitant pancreatic cancer with AIP, and pancreatoduodenectomy was performed. The formalin-fixed paraffin-embedded 4-μm sections were used for hematoxylin and eosin staining, Elastica-Masson staining and IgG4 immunostaining (mouse anti-human IgG4 monoclonal antibody; dilution, 1:400; catalog no., GTX75819; GeneTex, Irvine, CA, USA). Pathological examination revealed diffuse lymphoplasmacytic infiltrate with fibrosis, periductal lymphoplasmacytic infiltrate in the pancreatic head mass: (A) x40 and (B) x400 magnification. (C) Elastica-Masson staining showing obliteratorive phlebitis in this specimen. (D) An abundance of IgG4-positive cells was observed in the lymphoplasmacytic infiltrate (>10 cells/high power field).
and obliterative phlebitis (Fig. 4A-C). The lymphoplasmacytic infiltrate included an abundance of IgG4-positive cells (>10 cells/high power field (HPF)) (Fig. 4D), which forms one of the histological criteria for AIP proposed by the Mayo Clinic (7). No malignant cells were found. Recurrent AIP was therefore diagnosed. Maintenance steroid therapy was resumed following surgery, and, at the time of writing the present study, no recurrent AIP in the pancreatic remnant has been identified for 4 years after surgery.

Discussion

AIP is a distinct form of pancreatitis characterized by the involvement of autoimmune mechanisms, such as hypergammaglobulinemia, increased serum levels of IgG, increased serum levels of IgG4 or the presence of autoantibodies (1). AIP has been associated with an effective response to steroid therapy (1). The pathological features of this disorder are characterized by periductal lymphoplasmacytic infiltrate and lymphoplasmacytic infiltrate showing abundant (>10 cells/HPF) IgG4-positive cells (7). This lymphoplasmacytic infiltration is often accompanied by storiform fibrosis and obliterative phlebitis (7). These characteristic features can distinguish AIP from normal chronic pancreatitis (7). The clinical spectrum of AIP includes sclerosing cholangitis, retroperitoneal fibrosis, hilar lymphadenopathy, salivary gland swelling and interstitial pneumonia (8). Some of these extrapancreatic lesions show pathological findings similar to those of pancreatic lesions (8).

AIP and pancreatic cancer share several characteristics; however, the therapeutic methods for each of these diseases are vastly different. Pancreatic cancer requires surgery, while steroid therapy is effective for AIP without the need for surgical intervention (4). It is therefore crucial to distinguish AIP from pancreatic cancer; however, in certain cases, differential diagnosis is challenging, despite the use of numerous different diagnostic modalities, such as CT and MRI scans, and ERCP. Nakazawa et al (9) reported that 7/37 (18.9%) patients with AIP underwent surgical intervention due to having been misdiagnosed with pancreatic or bile duct cancer. Kamisawa et al (4) also reported that 6/17 (35.3%) patients with focal mass-forming AIP were surgically treated due to the suspicion of pancreatic cancer.

Other studies have reported the utility of 18F-FDG-PET/CT for the differentiation of AIP from pancreatic cancer (2,3,5). 18F-FDG-PET/CT is a sensitive modality used for the diagnosis of malignancies. Since 18F-FDG uptake is caused by increased glucose utilization of tumor cells and is also observed at inflammatory sites, 18F-FDG uptake is a shared finding between AIP and pancreatic cancer. Kamisawa et al (5) concluded that 18F-FDG-PET/CT can assist in the differentiation between the two diseases by assessing 18F-FDG uptake patterns in the pancreas and extrapancreatic lesions. Lee et al (3) indicated that, in severe cases, using PET/CT can detect the presence of diffuse 18F-FDG uptake by the pancreas, or concomitant extrapancreatic uptake by the salivary glands, which can aid in differentiation. Ozaki et al (2) also reported that the typical 18F-FDG-PET findings for AIP are an irregular contour, longitudinal shape, heterogeneous accumulation and multiple localizations, whereas those for pancreatic cancer are a smooth contour, nodular shape, homogenous accumulation and solitary localization. Shigekawa et al (8) indicated that the accumulation patterns of 18F-FDG were nodular and solitary in the majority of cases of pancreatic cancer that they examined, and that the possibility of AIP was increased if the 18F-FDG accumulation in the pancreas had a longitudinal shape; however, nodular and solitary 18F-FDG accumulations were also observed in AIP, corresponding with focal changes in the pancreas on CT or ERCP. It was also reported that 18F-FDG uptake in extrapancreatic lesions, including the extra-abdominal lymph nodes, salivary glands, eyes and biliary duct, may be helpful in differentiating between pancreatic cancer and AIP.

Kamisawa et al (4) proposed an algorithm for the clinical management of a mass-like lesion on the pancreatic head, with particular emphasis on the differentiation between AIP and pancreatic cancer. They identified 6 imaging characteristics, a combination of CT and ERCP findings, that were highly suggestive of AIP. The findings were as follows: i) Delayed enhancement of the enlarged pancreas on CT scan; ii) a capsule-like rim on CT scan, iii) the presence of extrapancreatic lesions, such as salivary gland swelling, retroperitoneal mass or stenosis of the upper or intrahepatic bile duct on CT scan or ERCP; iv) ≥3 cm-long narrowed portion of the MPD on ERCP; v) skipped lesions of the MPD on ERCP, and vi) a maximal diameter of <5 mm of the upstream MPD on ERCP. In the present case, none of these imaging characteristics were observed. According to this algorithm, in cases with no positive imaging factors for AIP, surgery should be considered under the provisional diagnosis of pancreatic cancer.

Several studies have reported cases of pancreatic cancer complicated with AIP simultaneously (10-13) or during follow-up (14-18). Loos et al (15) reported a case of a patient who developed a metastatic adenocarcinoma of the pancreaticobiliary system within a year after the histologically confirmed diagnosis of AIP. In addition, among the reports, 3 patients were diagnosed with pancreatic cancer during maintenance steroid therapy (16-18). In general, the risk of pancreatic cancer is markedly increased in patients with chronic pancreatitis (14); however, the association between AIP and pancreatic cancer remains unknown. Based on earlier reports of cancer development during the course of maintenance steroid therapy for AIP, three key findings of the present study, and the algorithm proposed by Kamisawa et al (4), the patient was diagnosed with pancreatic cancer during the course of maintenance steroid therapy for AIP, and pancreatectoduodenectomy was performed. The aforementioned key findings of the present study were the following: i) Detection by PET/CT scan of a well-circumscribed, solitary, nodular and homogenous 18F-FDG uptake at the same area where a pancreatic head mass was identified; ii) no extrapancreatic uptake; and iii) normal serum IgG4 levels. Pathological examination revealed diffuse lymphoplasmacytic infiltrate with fibrosis, periductal infiltrate, obliterative phlebitis, IgG4-positive cells and absence of malignant cells; therefore, post-treatment relapse of AIP was eventually diagnosed.

At the time of writing the present study, no recurrent AIP in the pancreatic remnant of the patient had been identified for 4 years after surgery. Of note, authors from the Mayo Clinic recently reported that the relapse rate of AIP patients who underwent pancreatectoduodenectomy as the initial treatment
was markedly lower than that of patients who had not undergone pancreatectoduodenectomy (the corticosteroid-treated group) (19). While the underlying mechanisms are unclear, this is a noteworthy observation that requires further study.

In summary, the current study reported the case of a patient who presented with a new mass at the pancreatic head and an upstream dilatation of the MPD while receiving a maintenance dosage of steroids in the remission phase of AIP. The present study highlights the challenges faced by clinicians in the diagnosis and management of AIP in remission. In certain cases, the differentiation between pancreatic cancer and AIP remains difficult, despite the use of the latest diagnostic modalities.

References

1. Okazaki K, Kawa S, Kamisawa T, Naruse S, Tanaka S, Nishimori I, Ohara H, Ito T, Kiriya S, Inui K, et al: Clinical diagnostic criteria of autoimmune pancreatitis: Revised proposal. J Gastroenterol 41: 626–631, 2006.
2. Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, Momose M, Kadoya M, Miyata K, Aizawa T and Kawa S: Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol 43: 144–151, 2008.
3. Lee TY, Kim MH, Park do H, Seo DW, Lee SK, Kim JS and Lee KT: Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 193: 343–348, 2009.
4. Kamisawa T, Imai M, Yui Chen P, Tu Y, Egawa N, Tsuruta K, Okamoto A, Suzuki M and Kamata N: Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas 37: e62–e67, 2008.
5. Kamisawa T, Takum K, Anjiki H, Egawa N, Kurata M, Honda G and Tsuruta K: FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 57: 447–450, 2010.
6. Kamisawa T, Okazaki K, Kawa S, Shimosegawa T and Tanaka M: Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society: Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 45: 471–477, 2010.
7. Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L, Clain JE, Pearson RK, Petersen BT, Vege SS and Farnell MB: Diagnosis of autoimmune pancreatitis: The Mayo Clinic experience. Clin Gastroenterol Hepatol 4: 1010–1016, 2006.
8. Shigekawa M, Yamao K, Sawaki A, Hara K, Takagi T, Bhatia V, Nishio M, Tamaki T, El-Amin H, Sayed Zel-A and Mizuno N: Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? J Hepatobiliary Pancreat Sci 17: 269–274, 2010.
9. Nakazawa T, Ohara H, Sano H, Ando T, Imai H, Takada H, Hayashi K, Kitajima Y and Joh T: Difficulty in diagnosing autoimmune pancreatitis by imaging findings. Gastrointest Endosc 65: 99–108, 2007.
10. Inoue H, Miyatani H, Sawada Y and Yoshida Y: A case of pancreas cancer with autoimmune pancreatitis. Pancreas 33: 208–209, 2006.
11. Witkiewicz AK, Kennedy EP, Kenny L, Yeo CJ and Hruban RH: Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: Case report and review of the literature. Hum Pathol 39: 1548–1551, 2008.
12. Motosugi U, Ichikawa T, Yamaguchi H, Nakazawa T, Katoh R, Itakura J, Fuji H, Sato T, Araki T and Shimizu M: Small invasive ductal adenocarcinoma of the pancreas associated with lymphoplasmacytic sclerosing pancreatitis. Pathol Int 59: 744–747, 2009.
13. Chandrasegaram MD, Chiam SC, Nguyen NQ, Ruszkiewicz A, Chung A, Neo EL, Chen JW, Worthley CS and Brooke-Smith ME: A case of pancreatic cancer in the setting of autoimmune pancreatitis with nondiagnostic serum markers. Case Rep Surg 2013: 890923, 2013.
14. Ghazale A and Chari S: Is autoimmune pancreatitis a risk factor for pancreatic cancer? Pancreas 35: 376, 2007.
15. Loos M, Esposito I, Hedderich DM, Ludwig L, Fingerle A, Friess H, Klopsell G and Büchler P: Autoimmune pancreatitis complicated by carcinoma of the pancreatobiliary system: A case report and review of the literature. Pancreas 40: 151–154, 2011.
16. Fukui T, Mitsuyama T, Takaoka M, Uchida K, Matsushita M and Okazaki K: Pancreatic cancer associated with autoimmune pancreatitis in remission. Intern Med 47: 151–155, 2008.
17. Kubota K, Iida H, Fujisawa T, Yoned M, Inamori M, Abe Y, Kikikoshi H, Saito S, Osbhiro H, Hakuta Y and Nakajima A: Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 66: 1142–1151, 2007.
18. Gupta R, Khosroshahi A, Shinagare S, Fernandez C, Ferrone C, Lauwers GY, Stone JH and Deshpande V: Does autoimmune pancreatitis increase the risk of pancreatic carcinoma? A retrospective analysis of pancreatic resections. Pancreas 42: 506–510, 2013.
19. Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, Pearson RK, Smyrk TC, Petersen BT, Topazian MD, et al: Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 139: 140–148; quiz e12-e13, 2010.